What Are the Determinations of Adult Progressive CKD? The Renal Impairment In Secondary Care (RIISC) Study
- Conditions
- Chronic Kidney Disease
- Registration Number
- NCT01722383
- Lead Sponsor
- University Hospital Birmingham NHS Foundation Trust
- Brief Summary
Chronic kidney disease (CKD) affects up to 16% of the adult population and is associated with significant morbidity and mortality. People at highest risk from progressive CKD are defined by a sustained decline in estimated glomerular filtration rate (eGFR) and/or the presence of significant albuminuria/proteinuria. Accurate mapping of the bio-clinical determinants of this group will enable improved risk stratification and direct the development of better targeted management for people with CKD. To address these requirements we have established the Renal Impairment in Secondary Care (RIISC) study; RIISC is enrolling a cohort of patients at high risk from progressive CKD and compiling a comprehensive and detailed bio-clinical phenotype, including vascular and oral health phenotyping, at enrolment and on subsequent follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 932
- Decline of eGFR of ≥5mls/min/year or ≥10mls/min/5years
- and/or urinary albumin-creatinine ration (ACR) ≥70 mg/mmol on three occasions
- and/or CKD 4 or 5 (pre-dialysis)
- renal replacement therapy
- immunosuppression
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of participants not alive up to 10 years
- Secondary Outcome Measures
Name Time Method Number of participants who reach End Stage Kidney Disease up to 10 years End Stage Kidney Disease describes a requirement for chronic dialysis treatment or a kidney transplant
Trial Locations
- Locations (1)
Queen Elizabeth Hospital Birmingham
🇬🇧Birmingham, West Midlands, United Kingdom